Search the Newsreel

Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen

Galectin Therapeutics Releases Q2 2026 Financial Results

Galectin Therapeutics Inc. (GALT) reported a wider net loss of $0.14 per share, or $9.1 million, for Q2 2026, an increase from $0.12 per share in the prior year. This reflects the company's continued investment in developing new drugs for fibrotic disease and cancer …

Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100

Galectin Therapeutics reports Q2 2026 net loss $9.2M, cash $13.3M, submits Phase 3 protocol

Galectin Therapeutics reported a Q2 2026 net loss of $9.2 million and held $13.3 million in cash. The company plans to submit a registrational Phase 3 protocol for belapectin in advanced MASH cirrhosis in Q3 2026, having aligned with the FDA on key trial …

Galectin Reports $9.1 Million Q2 Net Loss and FDA Phase 3 Agreement

Galectin Therapeutics (GALT) announced a net loss of $9.1 million for Q2 2026, or $0.14 per share, an increase from $7.6 million in the prior-year quarter. The company also reached an agreement with the FDA on key elements for its planned Phase 3 belapectin …

Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at Zacks Research

Zacks Research upgraded Galectin Therapeutics (NASDAQ:GALT) from a "strong sell" to a "hold" rating. The company received a consensus "Hold" rating and an $11.00 target price from various analysts. Galectin Therapeutics' stock opened at $3.14, with a market capitalization of $206.8 million, and the …

Alector, Inc. (NASDAQ:ALEC) Receives Consensus Recommendation of "Hold" from Brokerages

Alector, Inc. (NASDAQ:ALEC) has received a consensus "Hold" rating from eight brokerages, with an average 12-month price target of $3.625 against a current share price of $2.15. Despite beating quarterly earnings expectations with a smaller loss and higher revenue, the company remains deeply unprofitable, …

Industry Analysts Just Upgraded Their Alector, Inc. (NASDAQ:ALEC) Revenue Forecasts By 60%

Analysts have significantly upgraded Alector, Inc.'s near-term revenue forecasts by 60%, with the consensus for 2026 now standing at US$11 million, despite an expected 21% reduction in sales over the past year. While losses per share are predicted to decrease by 19% to US$0.86, …

HC Wainwright Issues Negative Outlook for Alector Earnings

HC Wainwright has lowered its Q3 and full-year 2026 earnings estimates for Alector, forecasting a deeper loss per share despite the company beating revenue expectations in its latest quarterly results. Alector's stock opened down 5.1% at $1.69, and analysts currently hold a consensus "Hold" …

Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Galectin Therapeutics Inc is anticipated to report a loss of 9 cents per share. This information is presented as an earnings preview by Reuters, accessible through TradingView News.

BofA Securities Maintains Alector(ALEC.US) With Sell Rating, Announces Target Price $1

BofA Securities has reiterated its Sell rating for Alector (ALEC.US) and set a target price of $1.00. This analyst action reflects a continued bearish outlook on the company's stock by the firm.

Analysts Offer Insights on Healthcare Companies: Alector (ALEC), Genmab (GMAB) and Xenon (XENE)

Analysts have provided insights on several healthcare companies, including Alector (ALEC), Genmab (GMAB), and Xenon (XENE). Alector received a Hold rating from William Blair, with a consensus Hold rating and a significant upside potential. Genmab was rated Buy by TD Cowen and TipRanks – …

Bank of America Securities Sticks to Its Sell Rating for Alector (ALEC)

H.C. Wainwright Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $5

H.C. Wainwright has reiterated its Buy rating for Alector (ALEC.US) and maintained its target price at $5. This indicates continued confidence from the analyst firm in the company's prospects.

Alector Inc (ALEC) Stock News Today

This article provides current stock news for Alector Inc (ALEC), a biotechnology and medical research company. As of the closing bell on August 7th, ALEC stock was trading at $1.780 USD, down 2.73%. The page indicates that more news regarding earnings, analyst ratings, and …

Alector (ALEC) Stock Faces Mounting Loss Pressure And Balance Sheet Risk

Alector Inc (ALEC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Alector Inc (ALEC) has an earnings forecast score of 6.50, ranking 325 out of 387 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $1.50, with a high of $5.00 and a low of $0.75, predominantly recommending a …

Alector, Inc. 2Q 2026: Revenue $3.32M, EPS $(0.21) — 10-Q Summary

Alector, Inc. reported its second-quarter 2026 results, showing a revenue of $3.32 million, a 57.8% decline year-over-year, and a net loss of $23 million, an improvement from the $30.5 million loss in the prior year. Diluted EPS improved to $(0.21) from $(0.30) YoY. The …

Alector, Inc. (ALEC) Stock Price, News, Quote & History

This page provides comprehensive financial data, news, and analysis for Alector, Inc. (ALEC), a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. It includes real-time stock price information, historical performance, key statistics, analyst ratings, and a company overview detailing its pipeline of …

Alector (NASDAQ:ALEC) Releases Earnings Results, Beats Expectations By $0.02 EPS

Alector earnings beat by $0.02, revenue topped estimates

Alector (NASDAQ: ALEC) reported better-than-expected Q2 earnings, with an EPS of $-0.21 against an analyst estimate of $-0.23, and revenue of $3.32M, surpassing the consensus of $2.12M. Despite the positive earnings, the company's stock has seen a -11.43% decline in the last three months, …

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

Alector, Inc. reported its second-quarter 2026 financial results, highlighting $172.8 million in cash, cash equivalents, and investments, projected to fund operations through 2027. The company is advancing its Alector Brain Carrier (ABC) platform, with AL137 for Alzheimer's disease targeting an IND submission in Q1 …

Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion

Galectin Therapeutics (GALT) converted $105.8 million in debt and accrued interest from its chairman and major shareholder, Richard E. Uihlein, into equity by issuing 34,376,167 common shares. This transaction significantly improved the company's balance sheet, increased Uihlein's voting power, and provides financial flexibility for …

Galectin Therapeutics (GALT) Projected to Announce Quarterly Earnings on Thursday

Alector (NASDAQ: ALEC) details Q2 loss, GSK exit and ABC pipeline focus

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Richard Uihlein converts GALT debt into 34,376,167 new shares

Richard E. Uihlein has converted approximately $105.8 million in debt owed by Galectin Therapeutics Inc. (GALT) into 34,376,167 shares of common stock. This transaction increases his beneficial ownership to 54,673,646 shares, representing about 49.30% of the outstanding common stock. Uihlein maintains sole voting and …

Galectin Therapeutics (GALT) director converts credit notes into stock

Richard E. Uihlein, a director and over-10% holder of Galectin Therapeutics (GALT), converted Line of Credit Convertible Notes totaling over $100 million into 34,376,167 common shares at prices of $3.00 and $4.05 per share. This transaction significantly increased his indirect common stock holdings via …

Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Galectin Therapeutics announced that its Chairman, Richard E. Uihlein, converted $105.8 million in outstanding debt, including principal and accrued interest, into 34,376,167 shares of common stock. This conversion significantly strengthens the company's balance sheet by eliminating substantial debt and reflects Mr. Uihlein's continued confidence …

Alector Inc expected to post a loss of 23 cents a share - Earnings Preview

Alector Inc (ALEC) is projected to report a loss of 23 cents per share. This earnings preview suggests analysts are anticipating a negative financial outcome for the company in its upcoming report.

Enterprise value to EBITDA forward of Alector, Inc. – NASDAQ:ALEC

This article provides a financial snapshot for Alector, Inc. (NASDAQ: ALEC), focusing on its enterprise value to EBITDA forward. It details that the market for Alector, Inc. is currently closed with no trades. The content is primarily a data presentation from TradingView, with disclaimers …

Alector Inc (0Z2) Q4 2023 Earnings Report - Results, Call & Slides

Alector Inc (0Z2) reported its Q4 2023 earnings, beating both EPS and revenue expectations. The company posted an actual EPS of -€0.42 against a consensus of -€0.67, and actual revenue of €13.17M versus an expected €7.66M, representing a YoY revenue growth of +5.19%. The …

Galectin Therapeutics (NASDAQ:GALT) Share Price Passes Above Two Hundred Day Moving Average - Here's Why